These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

7883 related articles for article (PubMed ID: 11832527)

  • 1. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
    Knowler WC; Barrett-Connor E; Fowler SE; Hamman RF; Lachin JM; Walker EA; Nathan DM;
    N Engl J Med; 2002 Feb; 346(6):393-403. PubMed ID: 11832527
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The diabetes prevention program and its global implications.
    Molitch ME; Fujimoto W; Hamman RF; Knowler WC;
    J Am Soc Nephrol; 2003 Jul; 14(7 Suppl 2):S103-7. PubMed ID: 12819312
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
    ; Knowler WC; Fowler SE; Hamman RF; Christophi CA; Hoffman HJ; Brenneman AT; Brown-Friday JO; Goldberg R; Venditti E; Nathan DM
    Lancet; 2009 Nov; 374(9702):1677-86. PubMed ID: 19878986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic syndrome components and their response to lifestyle and metformin interventions are associated with differences in diabetes risk in persons with impaired glucose tolerance.
    Florez H; Temprosa MG; Orchard TJ; Mather KJ; Marcovina SM; Barrett-Connor E; Horton E; Saudek C; Pi-Sunyer XF; Ratner RE; Goldberg RB;
    Diabetes Obes Metab; 2014 Apr; 16(4):326-33. PubMed ID: 24118860
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial.
    Orchard TJ; Temprosa M; Goldberg R; Haffner S; Ratner R; Marcovina S; Fowler S;
    Ann Intern Med; 2005 Apr; 142(8):611-9. PubMed ID: 15838067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Steps toward the primary prevention of type II diabetes mellitus. Various epidemiological considerations].
    Flórez H
    Invest Clin; 1997 Mar; 38(1):39-52. PubMed ID: 9235072
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of Lifestyle and Metformin Interventions on the Risk of Progression to Diabetes and Regression to Normal Glucose Regulation in Overweight or Obese People With Impaired Glucose Regulation.
    Herman WH; Pan Q; Edelstein SL; Mather KJ; Perreault L; Barrett-Connor E; Dabelea DM; Horton E; Kahn SE; Knowler WC; Lorenzo C; Pi-Sunyer X; Venditti E; Ye W;
    Diabetes Care; 2017 Dec; 40(12):1668-1677. PubMed ID: 29021207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes.
    ; Crandall J; Schade D; Ma Y; Fujimoto WY; Barrett-Connor E; Fowler S; Dagogo-Jack S; Andres R
    J Gerontol A Biol Sci Med Sci; 2006 Oct; 61(10):1075-81. PubMed ID: 17077202
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of lifestyle intervention and metformin on health-related quality of life: the diabetes prevention program randomized trial.
    Florez H; Pan Q; Ackermann RT; Marrero DG; Barrett-Connor E; Delahanty L; Kriska A; Saudek CD; Goldberg RB; Rubin RR;
    J Gen Intern Med; 2012 Dec; 27(12):1594-601. PubMed ID: 22692637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance.
    Herman WH; Hoerger TJ; Brandle M; Hicks K; Sorensen S; Zhang P; Hamman RF; Ackermann RT; Engelgau MM; Ratner RE;
    Ann Intern Med; 2005 Mar; 142(5):323-32. PubMed ID: 15738451
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Change in adiponectin explains most of the change in HDL particles induced by lifestyle intervention but not metformin treatment in the Diabetes Prevention Program.
    Goldberg RB; Temprosa M; Mele L; Orchard T; Mather K; Bray G; Horton E; Kitabchi A; Krakoff J; Marcovina S; Perreault L; White N;
    Metabolism; 2016 May; 65(5):764-775. PubMed ID: 27085783
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HbA1c as a predictor of diabetes and as an outcome in the diabetes prevention program: a randomized clinical trial.
    Diabetes Prevention Program Research Group
    Diabetes Care; 2015 Jan; 38(1):51-8. PubMed ID: 25336746
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alcohol consumption and diabetes risk in the Diabetes Prevention Program.
    Crandall JP; Polsky S; Howard AA; Perreault L; Bray GA; Barrett-Connor E; Brown-Friday J; Whittington T; Foo S; Ma Y; Edelstein SL;
    Am J Clin Nutr; 2009 Sep; 90(3):595-601. PubMed ID: 19640960
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance.
    Tuomilehto J; Lindström J; Eriksson JG; Valle TT; Hämäläinen H; Ilanne-Parikka P; Keinänen-Kiukaanniemi S; Laakso M; Louheranta A; Rastas M; Salminen V; Uusitupa M;
    N Engl J Med; 2001 May; 344(18):1343-50. PubMed ID: 11333990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The rationale, design, and baseline characteristics of PREVENT-DM: A community-based comparative effectiveness trial of lifestyle intervention and metformin among Latinas with prediabetes.
    Perez A; Alos VA; Scanlan A; Maia CM; Davey A; Whitaker RC; Foster GD; Ackermann RT; O'Brien MJ
    Contemp Clin Trials; 2015 Nov; 45(Pt B):320-327. PubMed ID: 26597415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized, 48-week, placebo-controlled trial of intensive lifestyle modification and/or metformin therapy in overweight women with polycystic ovary syndrome: a pilot study.
    Hoeger KM; Kochman L; Wixom N; Craig K; Miller RK; Guzick DS
    Fertil Steril; 2004 Aug; 82(2):421-9. PubMed ID: 15302293
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A clinical trial to maintain glycemic control in youth with type 2 diabetes.
    ; Zeitler P; Hirst K; Pyle L; Linder B; Copeland K; Arslanian S; Cuttler L; Nathan DM; Tollefsen S; Wilfley D; Kaufman F
    N Engl J Med; 2012 Jun; 366(24):2247-56. PubMed ID: 22540912
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical outcomes and cost-effectiveness of strategies for managing people at high risk for diabetes.
    Eddy DM; Schlessinger L; Kahn R
    Ann Intern Med; 2005 Aug; 143(4):251-64. PubMed ID: 16103469
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Diabetes Prevention Program. Design and methods for a clinical trial in the prevention of type 2 diabetes.
    The Diabetes Prevention Program Research Group
    Diabetes Care; 1999 Apr; 22(4):623-34. PubMed ID: 10189543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Body size and shape changes and the risk of diabetes in the diabetes prevention program.
    Fujimoto WY; Jablonski KA; Bray GA; Kriska A; Barrett-Connor E; Haffner S; Hanson R; Hill JO; Hubbard V; Stamm E; Pi-Sunyer FX;
    Diabetes; 2007 Jun; 56(6):1680-5. PubMed ID: 17363740
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 395.